Healthcare Economist December 11, 2025
That is the question asked in a recent Health Affairs Forefront article by Peter Neumann, Josh Cohen, Sean Sullivan and Feng Xie. They compare the CMS negotiated prices for Initial Price Applicability Year (IPAY) 2027 against value-based prices (using QALYs) from the Tufts Cost-Effectiveness Analysis (CEA) Registry.
The authors found that cost-effectiveness estimates varied among these drugs, with incremental cost-effectiveness ratios ranging...
Today's Sponsors
Today's Sponsor